ARTICLE | Clinical News
Zarnestra tipifarnib regulatory update
July 4, 2005 7:00 AM UTC
JNJ received a not approvable letter from FDA for an NDA for Zarnestra tipifarnib to treat elderly patients with newly diagnosed acute myeloid leukemia (AML). The company will review the letter to det...